NEW YORK (GenomeWeb News) – Early-stage in vitro diagnostics company Martell Biosystems is seeking approximately $3 million in venture capital to help set up shop near the Mayo Clinic in downtown Rochester, Minn., to develop a non-invasive, DNA amplification-based blood test to diagnose breast and other types of cancer, according to a company official.

Martell also needs the funding to finalize a licensing agreement for the core technology with the University of Pennsylvania, where it was developed, Martell President and COO Phil Messina told GWDN recently.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Sponsored by

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.